We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer

By LabMedica International staff writers
Posted on 12 Jun 2024
Print article
Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine)
Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine)

A computer program powered by artificial intelligence (AI) and trained on nearly half a million tissue images can effectively diagnose cases of adenocarcinoma, the most prevalent type of lung cancer.

The computer program developed and tested by researchers at NYU Langone Health (New York, NY, USA) and the University of Glasgow (Glasgow, UK) provides an unbiased, detailed, and reliable second opinion for patients and oncologists regarding the presence of the cancer and the possibility and timing of its return, also known as its prognosis. This is because the program incorporates structural features of tumors from 452 adenocarcinoma patients, who are among the more than 11,000 patients in the U.S. National Cancer Institute’s Cancer Genome Atlas. Importantly, the program operates independently and is "self-taught," deciding by itself which structural features are most critical for assessing the severity of the disease and its impact on tumor recurrence.

In their research, the algorithm, known as histomorphological phenotype learning (HPL), successfully differentiated between adenocarcinoma and similar types of lung cancer, such as squamous cell cancers, with 99% accuracy. The HPL program also demonstrated a 72% accuracy rate in predicting the likelihood and timing of cancer recurrence after treatment, surpassing the 64% accuracy achieved by pathologists who analyzed the same tumor images manually. The research team envisions that, with continued advances in understanding lung cancer biology, pathologists will increasingly review tissue samples on their computer rather than through traditional microscopy and will employ their AI program to further analyze and visualize these scans.

The researchers aim to use the HPL algorithm to assign each patient a score from 0 to 1 that reflects their statistical probability of survival and tumor recurrence for up to five years. They emphasize that the self-learning nature of HPL means the program's accuracy will improve as it processes more data over time. The team is now looking to develop similar AI-based programs for other types of cancer, such as breast, ovarian, and colorectal cancers, which will also incorporate key morphological and molecular data. Plans are also underway to enhance the precision of the adenocarcinoma HPL program by integrating additional data from hospital electronic health records, including information on other illnesses, diseases, income levels, and residential zip codes.

“Our new histomorphological phenotype learning program has the potential to offer cancer specialists and their patients a quick and unbiased diagnostic tool for lung adenocarcinoma that, once further testing is complete, can also be used to help validate and even guide their treatment decisions,” said study lead investigator Nicolas Coudray, PhD, a bioinformatics programmer at NYU Grossman School of Medicine and Perlmutter Cancer Center. “Patients, physicians, and researchers know they can rely on this predictive modeling because it is self-taught, provides explainable decisions, and is based only on the knowledge drawn specifically from each patient’s tissue, including such features as its proportion of dying cells and tumor-fighting immune cells and how densely packed the tumor cells are.” The study was published in Nature Communications on June 11, 2024.

Related Links:
NYU Langone Health
University of Glasgow

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.